HPTN Publications

Looking to submit your manuscript for review?

Submit your manuscript to the Manuscript Review Committee.

Filter publications by:

Sugarman J, Trumble I, Hamilton EL, Sarasvita R, Dumchev K, Viet H, Hoffman I, Miller W, Hanscom B . Reported Participation Benefits in International Hiv Prevention Research with People Who Inject Drugs. [HPTN 074]. Ethics Hum Res. , 41: 28-34

Year

2019

Ethics Hum Res

HPTN 074

Susan H Eshleman, Estelle Piwowar-Manning, Mariya V. Sivay, Barbara Debevec, Stephanie Veater, Laura McKinstry, Linda Gail Bekker, Sharon Mannheimer, Robert M. Grant, Margaret A. Chesney, Thomas J. Coates, Beryl A. Koblin, Jessica M. Fogel, Eshleman SH, Piwowar-Manning E, Sivay MV, Debevec B, Veater S, McKinstry L, Bekker LG, Mannheimer S, Grant RM, Chesney MA, Coates TJ, Koblin BA, Fogel JM . Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. J Clin Virol. 2018, 99-100: 67-70

Year

2018

J Clin Virol

HPTN 067

T Gamble, B Branson, D Donnell, HI Hall, G King, B Cutler, S Hader, D Burns, J Leider, AF Wood, KG Volpp, WM El-Sadr . Design of the HPTN 065 (TLC-Plus) Study: A Study to Evaluate the Feasibility of an Enhanced Test, Link-to-Care, Plus Treat Approach for HIV Prevention in the United States. Clin Trials. 2017, 14: 322-332

Year

2017

Clin Trials

HPTN 065

Taggart T, Mayer KH, Vermund SH, Huang S, Hayashi K, Ransome Y . Interaction of Religion/Spirituality With Internalized HIV Stigma, Depression, Alcohol Use, and Sexual Risk Among Black Men Who Have Sex With Men: The 6 City HPTN 061 Study. J Acquir Immune Defic Syndr. 2021, 87: e188-e197

Year

2021

J Acquir Immune Defic Syndr

HPTN 061

Takuva S, Karuna ST, Juraska M, Rudnicki E, Edupuganti S, Anderson M, De La Grecca R, Gaudinski MR, Sehurutshi A, Orrell C, Naidoo L, Valencia J, Villela LM, Walsh SR, Andrew P, Karg C, Randhawa A, Hural J, Gomez Lorenzo MM, Burns DN, Ledgerwood J, Mascola JR, Cohen M, Corey L, Mngadi K, Mgodi NM, HVTN 703/HPTN 081 and HVTN 704/HPTN 085 Study Teams. . Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.. J Acquir Immune Defic Syndr. 2022, 89: 405-413

Year

2022

J Acquir Immune Defic Syndr

HVTN 703/HPTN 081

Tedrow VA, Zelaya CE, Kennedy CE, Morin SF, Khumalo-Sakutukwa G, Sweat MD, Celentano DD . No "Magic Bullet": Exploring community mobilization strategies used in a multi-site community based randomized controlled trial: Project Accept (HPTN 043). AIDS Behav. 2012, 16: 1217-26

Year

2012

AIDS Behav

HPTN 043

Telisinghe L, Floyd S, MacLeod D, Schaap A, Dunbar R, Bwalya J, Bell-Mandla N, Piwowar-Manning E, Donnell D, Shaunaube K, Bock P, Fidler S, Hayes RJ, Ayles HM; HPTN 071 (PopART) study team . Incidence of self-reported tuberculosis treatment with community-wide universal testing and treatment for HIV and tuberculosis screening in Zambia and South Africa: A planned analysis of the HPTN 071 (PopART) cluster-randomised trial. PLoS Med. 2024, 21: e1004393

Year

2024

PLoS Med

HPTN 071

Theodore DA, Neradilek M, Gillespie K, Edupuganti S, Hinojosa JC, Lama JR, De La Grecca R, Wu YH, Davis A, Mangini D, Andrew P, Marovich MA, Zwerski S, Broder G, Andrasik MP, Castor D, Roxby AC, Cohen M, Huang Y, Karuna ST, Sobieszczyk ME. . Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085. J Acquir Immune Defic Syndr. 2025, 98: 340-345

Year

2025

J Acquir Immune Defic Syndr

HVTN 704/HPTN 085